spacer
spacer

PDBsum entry 2msh

Go to PDB code: 
protein ligands metals links
Hormone/growth factor PDB id
2msh

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
11 a.a.
Ligands
ACE
NH2
Metals
_RE
Theoretical model
PDB id:
2msh
Name: Hormone/growth factor
Title: Trithiol alpha melanocyte stimulating hormone cyclized through rhenium coordination
Structure: Alpha melanocyte stimulating hormone. Chain: a. Synonym: msh
Source: not given
Authors: M.F.Giblin,N.Wang,T.J.Hoffman,S.S.Jurisson,T.P.Quinn
Key ref:
M.F.Giblin et al. (1998). Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A, 95, 12814-12818. PubMed id: 9788997 DOI: 10.1073/pnas.95.22.12814
Date:
25-Sep-98     Release date:   30-Sep-98    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
No UniProt id for this chain
Struc: 11 a.a.
Key:    Secondary structure

 

 
DOI no: 10.1073/pnas.95.22.12814 Proc Natl Acad Sci U S A 95:12814-12818 (1998)
PubMed id: 9788997  
 
 
Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination.
M.F.Giblin, N.Wang, T.J.Hoffman, S.S.Jurisson, T.P.Quinn.
 
  ABSTRACT  
 
alpha-Melanocyte stimulating hormone (alpha-MSH) analogs, cyclized through site-specific rhenium (Re) and technetium (Tc) metal coordination, were structurally characterized and analyzed for their abilities to bind alpha-MSH receptors present on melanoma cells and in tumor-bearing mice. Results from receptor-binding assays conducted with B16 F1 murine melanoma cells indicated that receptor-binding affinity was reduced to approximately 1% of its original levels after Re incorporation into the cyclic Cys4,10, D-Phe7-alpha-MSH4-13 analog. Structural analysis of the Re-peptide complex showed that the disulfide bond of the original peptide was replaced by thiolate-metal-thiolate cyclization. A comparison of the metal-bound and metal-free structures indicated that metal complexation dramatically altered the structure of the receptor-binding core sequence. Redesign of the metal binding site resulted in a second-generation Re-peptide complex (ReCCMSH) that displayed a receptor-binding affinity of 2.9 nM, 25-fold higher than the initial Re-alpha-MSH analog. Characterization of the second-generation Re-peptide complex indicated that the peptide was still cyclized through Re coordination, but the structure of the receptor-binding sequence was no longer constrained. The corresponding 99mTc- and 188ReCCMSH complexes were synthesized and shown to be stable in phosphate-buffered saline and to challenges from diethylenetriaminepentaacetic acid (DTPA) and free cysteine. In vivo, the 99mTcCCMSH complex exhibited significant tumor uptake and retention and was effective in imaging melanoma in a murine-tumor model system. Cyclization of alpha-MSH analogs via 99mTc and 188Re yields chemically stable and biologically active molecules with potential melanoma-imaging and therapeutic properties.
 
  Selected figure(s)  
 
Figure 1.
Fig. 1. Model structures of APOMSH (Left), ReMSH (Center), and ReCCMSH (Right) derived from NMR analyses. The site of Re coordination is depicted by the filled circle in ReMSH and ReCCMSH molecules.
Figure 2.
Fig. 2. Imaging of a melanoma tumor in a mouse injected with 99mTcCCMSH. The -camera image of the melanoma-bearing mouse was acquired 30 min postinjection. The lateral image of the mouse with a 400-mg tumor shows a high degree of radioactivity localized in the tumor (b) with lesser amounts present in the kidneys (a), bladder (c), and tail vein injection site (d). The intensity of the -emission is color-coded high-to-low, ranging from white-yellow through orange, with dark red representing lowest values.
 

Literature references that cite this PDB file's key reference

  PubMed id Reference
21531292 H.M.Bigott-Hennkens, S.F.Dannoon, S.M.Noll, V.C.Ruthengael, S.S.Jurisson, and M.R.Lewis (2011).
Labeling, stability and biodistribution studies of (99m)Tc-cyclized Tyr(3)-octreotate derivatives.
  Nucl Med Biol, 38, 549-555.  
21510913 J.Le Gal, M.Gonera, M.A.Lelait, D.Servent, and C.Dugave (2011).
Chelate oxorhenium to assemble new integrin antagonists.
  J Inorg Biochem, 105, 880-886.  
21392860 M.Aufort, M.Gonera, M.A.Lelait, B.Czarny, L.Le Clainche, R.Thaï, A.Landra, M.Ruinart de Brimont, and C.Dugave (2011).
Synthesis, in vitro screening and in vivo evaluation of cyclic RGD analogs cyclized through oxorhenium and oxotechnetium coordination.
  Eur J Med Chem, 46, 1779-1788.  
20851156 K.Chen, and P.S.Conti (2010).
Target-specific delivery of peptide-based probes for PET imaging.
  Adv Drug Deliv Rev, 62, 1005-1022.  
20564045 P.D.Raposinho, J.D.Correia, M.C.Oliveira, and I.Santos (2010).
Melanocortin-1 receptor-targeting with radiolabeled cyclic α-melanocyte-stimulating hormone analogs for melanoma imaging.
  Biopolymers, 94, 820-829.  
19354275 D.Liu, D.Overbey, L.Watkinson, and M.F.Giblin (2009).
Synthesis and characterization of an (111)in-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR).
  Bioconjug Chem, 20, 888-894.  
19283279 M.Bartholomä, J.Valliant, K.P.Maresca, J.Babich, and J.Zubieta (2009).
Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals.
  Chem Commun (Camb), (), 493-512.  
19188158 W.Lu, C.Xiong, G.Zhang, Q.Huang, R.Zhang, J.Z.Zhang, and C.Li (2009).
Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres.
  Clin Cancer Res, 15, 876-886.  
  21437135 H.Hong, J.Sun, and W.Cai (2008).
Anatomical and molecular imaging of skin cancer.
  Clin Cosmet Investig Dermatol, 1, 1.  
18292870 K.Tanaka, and K.Fukase (2008).
PET (positron emission tomography) imaging of biomolecules using metal-DOTA complexes: a new collaborative challenge by chemists, biologists, and physicians for future diagnostics and exploration of in vivo dynamics.
  Org Biomol Chem, 6, 815-828.  
18183429 P.D.Raposinho, C.Xavier, J.D.Correia, S.Falcão, P.Gomes, and I.Santos (2008).
Melanoma targeting with alpha-melanocyte stimulating hormone analogs labeled with fac-[99mTc(CO)3]+: effect of cyclization on tumor-seeking properties.
  J Biol Inorg Chem, 13, 449-459.  
18387816 Y.Miao, and T.P.Quinn (2008).
Peptide-targeted radionuclide therapy for melanoma.
  Crit Rev Oncol Hematol, 67, 213-228.  
17504162 G.Liu, and D.J.Hnatowich (2007).
Labeling biomolecules with radiorhenium: a review of the bifunctional chelators.
  Anticancer Agents Med Chem, 7, 367-377.  
17691760 J.E.Cyr, D.A.Pearson, C.A.Nelson, B.A.Lyons, Y.Zheng, J.Bartis, J.He, M.V.Cantorias, R.C.Howell, and L.C.Francesconi (2007).
Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agent.
  J Med Chem, 50, 4295-4303.  
17998097 L.Wei, Y.Miao, F.Gallazzi, T.P.Quinn, M.J.Welch, A.L.Vāvere, and J.S.Lewis (2007).
Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma.
  Nucl Med Biol, 34, 945-953.  
17651039 Y.Miao, T.Shelton, and T.P.Quinn (2007).
Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model.
  Cancer Biother Radiopharm, 22, 333-341.  
16568178 P.Blower (2006).
Towards molecular imaging and treatment of disease with radionuclides: the role of inorganic chemistry.
  Dalton Trans, (), 1705-1711.  
16705688 Y.Ye, M.Liu, J.L.Kao, and G.R.Marshall (2006).
Novel trihydroxamate-containing peptides: design, synthesis, and metal coordination.
  Biopolymers, 84, 472-489.  
16094474 F.Zobi, B.Spingler, and R.Alberto (2005).
Structure, reactivity and solution behaviour of [Re(ser)(7-MeG)(CO)(3)] and [Re(ser)(3-pic)(CO)(3)]: "nucleoside-mimicking" complexes based on the fac-[Re(CO)(3)](+) moiety.
  Dalton Trans, (), 2859-2865.  
14523936 A.N.Eberle, and S.Froidevaux (2003).
Radiolabeled alpha-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium.
  J Mol Recognit, 16, 248-254.  
  12851339 S.Froidevaux, M.Calame-Christe, L.Sumanovski, H.Tanner, and A.N.Eberle (2003).
DOTA alpha-melanocyte-stimulating hormone analogues for imaging metastatic melanoma lesions.
  Ann N Y Acad Sci, 994, 378-383.  
14517900 Y.Ye, M.Liu, J.L.Kao, and G.R.Marshall (2003).
Peptide-bond modification for metal coordination: peptides containing two hydroxamate groups.
  Biopolymers, 71, 489-515.  
11877745 J.Chen, Z.Cheng, Y.Miao, S.S.Jurisson, and T.P.Quinn (2002).
Alpha-melanocyte-stimulating hormone peptide analogs labeled with technetium-99m and indium-111 for malignant melanoma targeting.
  Cancer, 94, 1196-1201.  
12216078 Y.Miao, N.K.Owen, D.Whitener, F.Gallazzi, T.J.Hoffman, and T.P.Quinn (2002).
In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy.
  Int J Cancer, 101, 480-487.  
11774230 G.R.Marshall (2001).
Peptide interactions with G-protein coupled receptors.
  Biopolymers, 60, 246-277.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time.

 

spacer

spacer